English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Both ligand‐dependent and ligand‐independent activation of estrogen receptor (ER)α is modulated by receptor phosphorylation and results in activation of the ERα‐dependent pathways that are involved in endometrioid endometrial cancer ( EEC ) pathogenesis. It is also known that the mammalian target of rapamycin ( mTOR )/p70 S6 kinase 1 ( S6K 1) and  MAPK /p90 ribosomal S6 kinase ( RSK ) signaling pathways coordinately regulate phosphorylated‐ ER α at Ser 167  (p‐Ser 167 ‐ ER α). However, the expression of p‐Ser 167 ‐ ER α in  EEC  and its prognostic role in  ECC  is largely unexplored. The purpose of the present study was to investigate the expression of p‐Ser 167 ‐ ER α in  ECC  and its relationship with prognosis. Immunohistochemical staining of primary  EEC  surgical specimens ( n  = 103) was carried out using antibodies specific for p‐Ser 167 ‐ ER α and for p‐ mTOR /p‐S6K1 and p‐ MAPK /p‐ RSK . The correlation of p‐Ser 167 ‐ ER α expression with clinicopathological features and survival of  ECC  was studied. Patients that were positive for nuclear p‐Ser 167 ‐ ER α had significantly shorter relapse‐free survival, and although the result was not significant, levels of nuclear p‐Ser 167 ‐ERα tended to be higher in advanced‐stage  ECC  patients. Nuclear p‐Ser 167 ‐ ER α was significantly positively correlated with p‐ MAPK  and p‐ S6K 1, and with significantly shorter relapse‐free survival in  EEC .

Relation between outcomes and expression of estrogen receptor‐α phosphorylated at Ser 167 in endometrioid endometrial cancer